LiquidLung Receives Notice of Allowance from U.S. Patent and Trademark Office, Unveils Novel RNA Technology for Non-Invasive Lung Cancer Detection

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--LiquidLung, Inc., a biotechnology company dedicated to radically improving the detection, diagnosis and treatment of pulmonary disease, is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application No. 17/003,775 for claims related to the non-invasive...

Click to view original post